{
}
The global Stem Cell Manufacturing market is projected to grow from USD 14.49 billion in 2025 to USD 34.54 billion by 2032, with a CAGR of 13%. The report provides insights into market trends, competitive landscape, and key players, including Lonza Group and Corning Incorporated, while analyzing challenges and opportunities within the industry.
The semaglutides market is projected to grow from $20.54 billion in 2023 to $36.87 billion by 2028, driven by rising diabetes prevalence and increased demand for effective treatments. Key players are innovating with GLP-1 receptor analogues and oral formulations to enhance patient adherence and reduce side effects. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
The North America oncology drugs market, valued at USD 10.13 billion in 2023, is projected to grow at a CAGR of 10.38%, reaching USD 27.20 billion by 2033. Key drivers include advances in cancer research, rising cancer prevalence, and increasing demand for personalized medicine, while challenges include high drug costs and stringent regulations. The market is segmented into cytotoxic, targeted, and hormonal drugs, with targeted therapies expected to dominate due to their effectiveness and reduced toxicity.
Takeda Pharmaceutical Company reported a 13.4% increase in revenue for the six months ending September 30, 2024, reaching JPY 2,384.0 billion, with operating profit soaring by 194% to JPY 350.6 billion and net profit up 352.3% to JPY 187.4 billion. Key growth drivers included Plasma-Derived Therapies, Gastroenterology, and Oncology, despite a decline in Neuroscience revenue due to generic competition. Looking ahead, the company anticipates revenue of JPY 4,480.0 billion for the fiscal year ending March 31, 2025, supported by strategic investments and product launches.
Takeda Pharmaceutical Company Limited reported significant growth for the half year ended September 30, 2024, with sales reaching JPY 2,384,028 million, up from JPY 2,101,707 million the previous year. Net income surged to JPY 187,294 million, compared to JPY 41,365 million a year ago. Basic earnings per share from continuing operations increased to JPY 118.85, while diluted earnings per share rose to JPY 117.11.
Takeda Pharmaceutical Co. has raised its full-year operating income forecast by 18% to ¥265 billion ($1.7 billion) following a strong second quarter driven by key drug sales and cost savings in North America. The previous outlook for the fiscal year ending March 2025 was ¥225 billion.
Takeda Pharmaceutical Company and Boston Medical Center (BMC) have announced a collaboration aimed at reducing greenhouse gas emissions in the healthcare sector, particularly from regulated medical waste. This partnership will involve waste audits and the piloting of new technologies to identify and mitigate emission hotspots, while also sharing best practices with other organizations. Takeda's commitment to achieving net-zero emissions by 2035 aligns with BMC's focus on sustainability and health equity, addressing environmental challenges that impact community well-being.
Takeda has terminated its partnership with Wave Life Sciences regarding the investigational antisense oligonucleotide WVE-003 for Huntington’s disease, after investing $260 million since their 2018 agreement. Despite this unexpected withdrawal, Wave retains full responsibility for WVE-003 and anticipates regulatory feedback on accelerated approval by the end of 2024. The biotech continues to advance its pipeline, including successful RNA editing demonstrations and improvements in treatments for other conditions.
Takeda Pharmaceutical Company Limited
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
stem cell manufacturing market poised for significant growth through 2032
United States Dollar
Thermo Fisher Scientific Inc.
Daiichi Sankyo Company, Limited
AbbVie Inc.
Lonza Group AG
Corning Incorporated
Danaher Corporation
Glaxosmithkline plc
Bristol-Myers Squibb Company
FUJIFILM Holdings Corporation
Takeda Pharmaceutical Company Limited
Alice Mutum
Viju Shah
Show more
09:48 28.04.2025
semaglutides market projected to reach 36.87 billion by 2028
United States Dollar
Adocia SA
Sanofi SA
Eli Lilly and Company
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Dr. Reddy's Laboratories Limited
Boehringer Ingelheim International GmbH
Glaxosmithkline plc
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Novartis International AG
Bristol-Myers Squibb Company
Novo Nordisk A/S
Cipla Limited
Biocon Limited
Teva Pharmaceutical Industries Ltd
AstraZeneca PLC
Amgen Inc.
ITA
IND
FRA
IDN
CAN
ESP
BRA
USA
RUS
CHN
DEU
AUS
JPN
GBR
KOR
Show more
10:12 06.01.2025
rth america oncology drugs market projected to reach 27.20 billion by 2033
United States Dollar
Novartis AG
Gilead Sciences, Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Johnson & Johnson
Amgen Inc.
Bristol-Myers Squibb Company
Biogen Inc.
AstraZeneca PLC
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Celgene Corporation
AbbVie Inc.
Eli Lilly and Company
USA
Show more
14:29 22.11.2024
Takeda Pharmaceutical reports strong revenue growth and profit surge in 2024
05:44 01.11.2024
takeda pharmaceutical reports significant earnings growth for first half of 2024
11:21 31.10.2024
takeda raises full-year operating income forecast after strong second quarter
07:16 31.10.2024
takeda and boston medical center collaborate to reduce healthcare emissions
United States Dollar
Takeda Pharmaceutical Company Limited
Boston Medical Center Health Plan Inc.
JPN
USA
Robert Biggio
Teresa Bitetti
09:00 24.10.2024
takeda ends partnership with wave life sciences after 260 million investment
09:00 16.10.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: